StoxApollo Hospitals Enterprise vs Zydus Lifesciences: share price & financials comparison
NSE: APOLLOHOSP vs ZYDUSLIFE · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Apollo Hospitals Enterprise vs Zydus Lifesciences at a glance
Apollo Hospitals Enterprise (APOLLOHOSP) has a market capitalisation of ₹1,21,453 Cr, against ₹1,19,550 Cr for Zydus Lifesciences (ZYDUSLIFE). Over the past year Zydus Lifesciences has returned +19.4%, compared with +7.5% for Apollo Hospitals Enterprise. On valuation, Zydus Lifesciences trades at a lower P/E of 28.6 versus 54.2. Apollo Hospitals Enterprise earns a higher return on equity (21.1% vs 15.0%). Apollo Hospitals Enterprise comes out ahead on growth. Zydus Lifesciences comes out ahead on size, valuation, profitability, financial health, momentum and technicals. Across the scored metrics below, Apollo Hospitals Enterprise leads on 5 and Zydus Lifesciences on 13. On StoxGud's 10-point checklist, Apollo Hospitals Enterprise scores 8/10 and Zydus Lifesciences scores 10/10.
| Metric | Apollo Hospitals Enterprise | Zydus Lifesciences |
|---|---|---|
| Size | ||
| Market cap | ₹1,21,453 Cr | ₹1,19,550 Cr |
| Revenue (latest FY) | ₹25,228 Cr | ₹27,148 Cr |
| Net profit (latest FY) | ₹1,942 Cr | ₹5,040 Cr |
| Valuation | ||
| P/E | 54.2 | 28.6 |
| P/B | 11.45 | 4.30 |
| Dividend yield | 0.24% | 0.93% |
| Profitability | ||
| Return on equity | 21.1% | 15.0% |
| Net profit margin | 8.1% | 13.8% |
| Operating margin | 15.4% | 27.0% |
| Growth | ||
| Revenue growth (YoY) | +20.8% | +29.2% |
| Net profit growth (YoY) | +32.0% | -26.5% |
| Revenue CAGR (multi-year) | +19.0% | +12.4% |
| Financial health | ||
| Debt to equity | 0.53 | 0.48 |
| Momentum | ||
| 1-month return | +6.7% | +3.9% |
| 1-year return | +7.5% | +19.4% |
| 3-year CAGR | +17.8% | +27.0% |
| 5-year CAGR | +13.9% | +19.4% |
| 10-year CAGR | +20.8% | +12.1% |
| Distance from 52W high | -6.9% | -3.8% |
| Technicals | ||
| RSI (14) | 66 | 67 |
| Price vs 200-day avg | +3.9% | +15.1% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Apollo Hospitals Enterprise | Zydus Lifesciences |
|---|---|---|
| Price above 50-day average | ✓ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✓ | ✓ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✓ | ✓ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✗ | ✓ |
| P/E below industry median | ✗ | ✓ |
| Score | 8/10 | 10/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Apollo Hospitals Enterprise or Zydus Lifesciences?
Apollo Hospitals Enterprise has a market cap of ₹1,21,453 Cr and Zydus Lifesciences has a market cap of ₹1,19,550 Cr as of 06 Nov 2026.
Which has a lower P/E, Apollo Hospitals Enterprise or Zydus Lifesciences?
Zydus Lifesciences has the lower P/E: Apollo Hospitals Enterprise trades at 54.2 and Zydus Lifesciences at 28.6.
Which gave better returns in the last year, Apollo Hospitals Enterprise or Zydus Lifesciences?
Zydus Lifesciences did better: Apollo Hospitals Enterprise returned +7.5% and Zydus Lifesciences returned +19.4% over one year.
Is Apollo Hospitals Enterprise or Zydus Lifesciences a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Apollo Hospitals Enterprise scores 8/10 and Zydus Lifesciences scores 10/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.